DAGola

DAGola is a biotechnology company specializing in the design and development of next-generation targeted protein degraders (TPDs). Leveraging a proprietary platform based on Directed Acyclic Graphs (DAGs), the company creates multivalent ligands with optimized binding affinities and pharmacokinetic properties. DAGola's technology aims to address undruggable targets in oncology and neurodegeneration by facilitating the selective degradation of disease-causing proteins. As a spin-off from the University of Santiago de Compostela, the company integrates advanced computational design with synthetic chemistry to accelerate drug discovery.